8-K: Verrica Q3 Revenue Jumps, YCANTH Sales Double

Verrica Pharmaceuticals reported a significant increase in third-quarter 2025 revenue, driven by YCANTH sales and milestone payments, alongside positive regulatory feedback for its pipeline assets.

Summary

• Total revenue for the third quarter of 2025 was $14.3 million, a substantial increase from a negative $1.8 million in the same period of 2024.
• Product revenue, net, primarily from YCANTH, was $3.6 million in Q3 2025, compared to negative $1.9 million in Q3 2024.
• License and collaboration revenue reached $10.7 million in Q3 2025, including a $10 million milestone payment from Torii Pharmaceutical for YCANTH approval in Japan.
• YCANTH dispensed applicator units increased by 120% for the nine months ended September 30, 2025, totaling 37,642 units compared to 17,119 units in the prior year.
• The company reported a net loss of $0.3 million in Q3 2025, a significant improvement from a $22.9 million net loss in Q3 2024.
• Non-GAAP net income for Q3 2025 was $1.2 million, compared to a non-GAAP net loss of $20.2 million in Q3 2024.
• Cash and cash equivalents stood at $21.1 million as of September 30, 2025.
• Received positive feedback from the FDA regarding the Phase 3 study design for VP-315 in basal cell carcinoma, which is expected to support a New Drug Application (NDA) filing.
• Received positive feedback from the European Medicines Agency (EMA) supporting a Marketing Authorization Application (MAA) filing for YCANTH for molluscum without the need for additional Phase 3 studies.
• Initiated clinical startup activities for a global Phase 3 program for YCANTH in common warts with Japanese partner Torii Pharmaceutical, with first patient enrollment in the U.S. expected by year-end 2025.
• Operating expenses for the nine months ended September 30, 2025, were reduced by nearly half compared to the same period in 2024.

Sentiment

Score: 8

Explanation: The filing reports strong financial improvements, significant revenue growth, and positive regulatory and clinical advancements for key pipeline assets, indicating robust operational execution and future growth potential despite a decrease in cash balance.

Positives

• Total revenue for Q3 2025 significantly increased to $14.3 million from -$1.8 million in Q3 2024.
• YCANTH product revenue, net, improved to $3.6 million in Q3 2025 from -$1.9 million in Q3 2024.
• License and collaboration revenue surged to $10.7 million in Q3 2025, driven by a $10 million milestone payment.
• YCANTH dispensed applicator units more than doubled year-over-year, showing a 120% increase for the nine months ended September 30, 2025.
• Net loss dramatically reduced to $0.3 million in Q3 2025 from $22.9 million in Q3 2024.
• Achieved non-GAAP net income of $1.2 million in Q3 2025, a significant turnaround from a $20.2 million non-GAAP net loss in Q3 2024.
• Operating expenses were nearly halved for the nine months ended September 30, 2025, demonstrating strong cost management.
• Received positive FDA feedback on the Phase 3 study design for VP-315 in basal cell carcinoma, paving the way for an NDA filing.
• Received positive EMA feedback for YCANTH for molluscum, potentially allowing MAA filing in Europe without further Phase 3 studies.
• Secured a $10 million cash milestone payment for YCANTH approval in Japan.
• Initiated a global Phase 3 program for YCANTH in common warts, expanding its market potential.
• Presented new data on VP-315 showing a 97% objective response rate and 86% reduction in overall tumor size in basal cell carcinoma, suggesting immune system engagement.

Negatives

• Cash and cash equivalents decreased to $21.1 million as of September 30, 2025, from $46.3 million as of December 31, 2024.
• Despite significant improvement, the company still reported a GAAP net loss for both Q3 2025 ($0.3 million) and YTD 2025 ($9.8 million).
• Interest income decreased by $0.5 million for the nine months ended September 30, 2025, primarily due to a lower cash balance.

Risks

• Risks and uncertainties related to market conditions could cause actual results to differ materially from forward-looking statements.
• Satisfaction of customary closing conditions related to the proposed public offering is a risk that could impact actual results.
• Other risks and uncertainties described in Verrica's Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings.

Future Outlook

The company expects to enroll the first patient in the United States for its global Phase 3 program of YCANTH in common warts by the end of 2025. YCANTH Rx, a new non-dispensing pharmacy option, is anticipated to launch in the fourth quarter of 2025. The sales force is planned to increase to 50 representatives in 2026. The manufacturing transfer of YCANTH applicators to Torii for sales in Japan is expected to occur in stages over the next several years. The FDA's alignment on the VP-315 Phase 3 program design is expected to support a New Drug Application filing. The company is also exploring potential partnering and non-dilutive financing discussions for its late-stage programs.

Management Comments

• "In the third quarter, Verrica achieved multiple commercial, corporate, scientific and regulatory milestones providing a strong foundation for future growth in YCANTH as well as significant upside potential from our late-stage clinical pipeline."
• "For the nine months ending September 30, 2025, we dispensed 37,642 applicator units compared to 17,119 units in the prior year, representing a 120% increase. I commend our team for more than doubling dispensed units of YCANTH over this period while reducing operating expenses by nearly half."
• "Each of these development opportunities represent meaningful future growth potential for Verrica, and together we believe they compose one of the most advanced portfolios of late-stage product candidates in dermatology."
• "Recent interest in Verrica's pipeline candidates at multiple scientific and business conferences has demonstrated the potential of our portfolio, enabling potential partnering and other non-dilutive financing discussions to help support further development and commercialization efforts for these late-stage programs."

Industry Context

Verrica Pharmaceuticals operates in the specialized dermatology therapeutics market, focusing on conditions like molluscum contagiosum, common warts, and basal cell carcinoma. The significant increase in YCANTH sales and positive regulatory feedback for both YCANTH in Europe and VP-315 in oncology demonstrate strong execution in addressing unmet medical needs. The company's strategic focus on expanding YCANTH's indications and geographic reach, alongside advancing its oncology pipeline, positions it to capitalize on growing demand in these dermatological segments. The reduction in operating expenses while simultaneously advancing multiple programs suggests efficient resource allocation in a competitive pharmaceutical landscape.

Stakeholder Impact

• Shareholders: Positive impact due to significant revenue growth, reduced net losses, achievement of non-GAAP net income, and advancements in the product pipeline, suggesting strong future growth potential.
• Employees: Positive impact with the planned increase in the sales force, indicating company expansion.
• Customers (Patients): Positive impact through the upcoming launch of YCANTH Rx for improved access and the continued development of treatments for molluscum, common warts, and basal cell carcinoma.
• Partners (Torii Pharmaceutical): Continued collaboration and receipt of milestone payments reinforce the strength of the partnership.
• Creditors (OrbiMed): The decrease in interest expense due to a lower principal balance suggests effective debt management.

Next Steps

• Launch YCANTH Rx, a new non-dispensing pharmacy option, in the fourth quarter of 2025.
• Achieve first patient enrollment in the United States for the global Phase 3 program of YCANTH in common warts by the end of 2025.
• Increase the size of the sales force to 50 representatives in 2026.
• Conduct long-term follow-up studies for VP-315 as post-approval commitments.
• Initiate manufacturing transfer to Torii for YCANTH applicators to be sold in Japan, expected to take place in stages over the next several years.
• Continue potential partnering and non-dilutive financing discussions for late-stage programs.

Key Dates

Recommendation

The company demonstrated exceptional financial turnaround with a substantial increase in revenue and a dramatic reduction in net losses, achieving non-GAAP net income in Q3. Key product YCANTH sales more than doubled, and the pipeline received significant positive regulatory feedback for both European market entry and advancement of a promising oncology asset (VP-315) into Phase 3. These operational and strategic milestones, coupled with cost reductions and potential non-dilutive financing, position Verrica for strong future growth and warrant a 'strong buy' recommendation.

Keywords

Verrica Pharmaceuticals, VRCA, YCANTH, VP-102, molluscum contagiosum, basal cell carcinoma, VP-315, dermatology, Q3 earnings, financial results, biotechnology, pharmaceuticals, skin diseases, common warts, FDA, EMA, Torii Pharmaceutical, clinical trials, Phase 3, oncology